NRG-BR002
| Clinical Trial Title | A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Trial Status | Closed to Enrollment |
| Start Date | 06/05/2018 |
| Location | Doctors & Locations |
| Trial Type | Cancer - Adult Oncology |
| Specific Condition | Breast Cancer |
| Description | This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating limited metastatic breast cancer. |
| Eligibility Criteria |
Please contact Legacy Oncology Research for additional study inclusion/exclusion information. |
| IRB Number | Central IRB |
| Notes | https://clinicaltrials.gov/ct2/show/NCT02364557 |
| Principal Investigator | Andrew Kee, MD |
| Contact Name | Oncology Clinical Research |
| Contact Phone | 503-413-8199 |
| Contact Fax | 503-413-6920 |
| Contact E-Mail | oncologyresearch@lhs.org |
